Good MorningEquity markets rebounded on Wednesday, closing near the week's open after the CPI report came in as expected. As expected, inflation remains sticky, with headline consumer prices accelerating compared to the previous month and the core reading flat and at levels well above the Fed's target.
In this scenario, one of the Fed's mandates is covered - the labor market - and the other needs attention. This means the Fed may pause its rate-cutting cycle next week, contrary to the market's belief. The CME FedWatch Tool is pricing a nearly 100% chance for a 25 basis point rate cut.
Thursday's hurdle is the PPI index. The PPI is a leading indicator of inflation and will give a clue as to what to expect from the CPI next month. If it comes in hotter than expected, it could reinvigorate fear of the Fed and what higher-for-longer interest rates will do for the economy. Even if the FOMC cuts next week, it is highly unlikely that rates will be reduced further in 2025 without improvement in the data. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Healthcare | |
Robotic surgery used to be fodder for science fiction movies. Not anymore. They are becoming more mainstream by the day. While fully autonomous surgeries in the medical sector are not yet a reality, the field is evolving quickly. Currently, robotics are being used to augment the surgeon’s ab... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | |
The end of a year is a time for rebalancing portfolios. Part of that process is analyzing what worked well in the current year and where your investment thesis may need to change in the new year.
Several factors suggest the market could deliver strong results in 2025. Lower corporate taxes... Read the Full Story |
|
Finance | |
It’s now the end of the investing year. As is customary, the biggest investment banks in the industry are starting to come out and issue their views for 2025. It is sort of the Super Bowl for the finance sector, where economists, strategists, and even quants come together to put forth the be... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Technology | |
The central processing unit (CPU) market is a cornerstone of the global technology sector, and it has long witnessed an intense rivalry between two industry titans: Advanced Micro Devices (NASDAQ: AMD) and Intel (NASDAQ: INTC).
For decades, these companies have competed fiercely to provide the f... Read the Full Story |
|
Consumer Discretionary | |
GameStop (NYSE: GME) shares edged higher following its Q3 release, but so what? The report included a surprise profit, but the underlying cause and business metrics align with the trend. This company continues to contract and is consuming itself at investors' expense. It only profited in Q3 becaus... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Technology | |
C3.ai Inc. (NYSE: AI) stock shrugged off an initial round of selling and was up about 3% in mid-day trading on heavy volume. This came the day after the company reported earnings for the second quarter of its 2025 fiscal year. C3.ai stock had dropped about 10% in the premarket as investors react... Read the Full Story |
|
Materials | |
The premium on gold’s price might be cooling off, especially as the geopolitical conflicts start to cool as nations gear up for the new United States administration. This is why gold’s price has ranged and struggled to break above $2,700 per ounce, making other discounted commodities, ... Read the Full Story |
|
Technology | |
MongoDB's (NASDAQ: MDB) share price slipped following the FQ3 release, which provided a classic dip buying opportunity. A business contraction didn’t cause the move, lack of growth, or weakness in the results of any kind, but rather, it was caused by the departure of long-time CFO Michael ... Read the Full Story |
|
Technology | |
The reaction to earnings reports can be fickle and illogical at times. Sometimes, the market will react one way and then completely reverse its sentiment. When a company beats top and bottom line estimates and raises guidance, the market is expected to push the stock higher, and vice versa when a ... Read the Full Story |
|
Consumer Discretionary | |
Share buyback authorizations are useful indicators to stay aware of. Share buybacks are often thought of as an indirect return of capital to shareholders. When a company buys back its shares, it lowers the number of outstanding shares. All else being equal, this increases earnings per share (EPS),... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida. | | View Today's Stock Pick |
|
